Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,586 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07448922RecruitingPhase 2
Study of SKB518 for advanced gynecologic cancers
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
ChongqingAges 18–75 - NCT05841771RecruitingPhase 2
Decitabine or azacitidine plus venetoclax after transplant
This trial tests two cancer medicines—decitabine or azacitidine (also called “hypomethylating agents”) plus venetoclax—given after an allogeneic stem cell transplant to help prevent relapse in people with high-risk AML or MDS. If you have measurable remaining leukemia cells after transplant, this study may be especially relevant.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06383871RecruitingPhase 1
A study of the new drug HRS-7058 for advanced solid tumors
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06735144RecruitingPhase 1/Phase 2
Testing FH-006 for advanced solid tumors
This trial tests a new drug called FH-006 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06658951Recruiting
HER2-targeted CAR-T cell therapy for advanced solid tumors
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
Zhengzhou, HenanAges 18–70 - NCT07556822RecruitingPhase 1
Testing HRS-3005 for Blood Cancers That Have Returned
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06649708RecruitingPhase 1/Phase 2
Study of HX044 for advanced solid tumors
This trial tests an experimental drug called HX044 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and helps shrink tumors.
Blacktown, New South WalesAges 18–75 - NCT07068932RecruitingPhase 1
Study of SHR-4506 for advanced solid tumors
This trial tests a new drug, SHR-4506, for people with advanced cancers that have stopped responding to standard treatments or cannot be treated with standard options. It aims to see if the drug is safe and helpful.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07065279Recruiting
JY231 injection for relapsed B-cell blood cancers
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
Kunming, YunnanAges 2–75 - NCT07007988RecruitingPhase 1
SIM0388 for fluid buildup in the abdomen from cancer
This trial tests a new drug, SIM0388, for people whose cancer has spread and caused fluid buildup in the belly. It aims to see if the drug is safe and can help reduce the fluid.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04807257RecruitingPhase 1/Phase 2
Targeted radiation for advanced skin tumors with a nano-therapy
This Phase 1/2 study tests an “Auger molecular therapy” treatment that uses targeted radiation on certain advanced cancers that have spread to the skin. It may help shrink or control skin tumors where the lesion size and location fit the treatment device.
TaipeiAges 18 years+ - NCT06258304RecruitingPhase 1
Testing a new immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug, GIGA-564, for people with advanced solid tumors that have not responded to or have returned after standard treatments. The goal is to see if the drug is safe and effective, and to find the best dose.
Bethesda, MarylandAges 18 years+ - NCT06468098RecruitingPhase 1
Study of IBI363 for advanced cancer
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07480733RecruitingPhase 2
Study of two drugs for advanced solid tumors
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07016490RecruitingPhase 1
Study of SSGJ-709 for advanced solid tumors
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
AdelaideAges 18 years+ - NCT06654440RecruitingPhase 2
Testing SHR-A2102 for advanced gynecological cancers
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06600789RecruitingPhase 1/Phase 2
Study of CT7439 for advanced solid tumors
This trial tests a new oral targeted drug (CT7439) for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Dallas, TexasAges 18 years+ - NCT06600022RecruitingPhase 1/Phase 2
Studying SCTB41 for advanced solid tumors
This trial tests a new drug called SCTB41 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it shrinks tumors.
Guangzhou, GuangdongAges 18 years+ - NCT07467122RecruitingPhase 1
TCR-T cell therapy for MAGE-A4-positive sarcomas and other tumors
This trial tests a personalized cell therapy called TCR-T that targets a protein called MAGE-A4 on tumor cells. It is for people with advanced sarcomas or similar cancers that have not responded to standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06668584RecruitingPhase 2
Olutasidenib to prevent cancer return after stem cell transplant
This study tests if a daily pill called olutasidenib can help keep your cancer from coming back after a stem cell transplant. It's for people with a specific IDH1 gene change and myeloid cancers like AML or MDS.
Houston, TexasAges 18–75 - NCT07399769RecruitingPhase 1/Phase 2
MSLN CAR-T therapy for advanced solid tumors
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT06958679RecruitingPhase 1
Study of SYS6005 for advanced solid tumors and lymphomas
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
TianjinAges 18 years+ - NCT06977945Recruiting
Testing FL-091 PET scans for cancer detection
This study tests a new imaging agent called FL-091 to see if it helps doctors find and stage cancers like head and neck, colorectal, or pancreatic cancer. You’ll get a PET scan that may give clearer pictures of tumors.
Wuhan, HubeiAges 18 years+ - NCT05772130Recruiting
Help family members get cancer genetic test results and counseling
This study tests a family-centered way to share cancer genetic testing results with close relatives, so more relatives get genetic counseling and testing. It may help your eligible family members understand their risk and get the right next steps.
Duarte, CaliforniaAges 18 years+
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,586 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.